[HTML][HTML] Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
F Vincenti, CP Larsen, J Alberu, B Bresnahan… - American journal of …, 2012 - Elsevier
The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if
earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3
year, phase III study in adults receiving a kidney transplant from a living or standard criteria
deceased donor. Patients were randomized to a more (MI) or less intensive (LI) regimen of
belatacept, or cyclosporine. 471/666 patients completed≥ 3 years of therapy. A total of
92%(MI), 92%(LI), and 89%(cyclosporine) of patients survived with a functioning graft. The …
earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3
year, phase III study in adults receiving a kidney transplant from a living or standard criteria
deceased donor. Patients were randomized to a more (MI) or less intensive (LI) regimen of
belatacept, or cyclosporine. 471/666 patients completed≥ 3 years of therapy. A total of
92%(MI), 92%(LI), and 89%(cyclosporine) of patients survived with a functioning graft. The …